Effect of endogenous galanin on glucose transporter 4 expression in cardiac muscle of type 2 diabetic rats

Peptides

Volumn 62, Issue , 2014, Pages 159-163

  Fang, Penghua ^a,b   Shi, Mingyi ^a   Guo, Lili ^a   He, Biao ^a   Wang, Qian ^b   Yu, Mei ^b   Bo, Ping ^a   Zhang, Zhenwen ^a  

^a YANGZHOU UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Cardiac muscle; Galanin; GLUT4; M35

Indexed keywords

GALANIN; GLUCOSE TRANSPORTER 4; INSULIN; RETINOL BINDING PROTEIN 4; BRADYKININ; GALANIN RECEPTOR; GALANIN-(1-13)-BRADYKININ-(2-9)-AMIDE; GLUCOSE BLOOD LEVEL; PEPTIDE FRAGMENT; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; GLUCOSE INFUSION; GLUCOSE TRANSPORT; HEART MUSCLE; HOMEOSTASIS; IMMUNOBLOTTING; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; BRADYKININ; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GALANIN; GENE EXPRESSION REGULATION; GLUCOSE TRANSPORTER TYPE 4; HUMANS; INSULIN; MYOCARDIUM; PEPTIDE FRAGMENTS; RATS; RECEPTORS, GALANIN; RETINOL-BINDING PROTEINS, PLASMA;

EID: 84908463838     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2014.10.001     Document Type: Article

References (35)

1. Adachi H, Ohno T, Oguri M, Oshima S, Taniguchi K. Effect of insulin sensitivity on severity of heart failure. Diabetes Res Clin Pract 2007;77:S258-62.
2. Ahren B, Pacini G, Wynick D, Wierup N, Sundler F. Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. Endocrinology 2004;145:3190-6.
3. Becker C, Sevilla L, Tomàs E, Palacin M, Zorzano A, Fischer Y. The endosomal compartment is an insulin-sensitive recruitment site for GLUT4 and GLUT1 glucose transporters in cardiac myocytes. Endocrinology 2001;142:5267-76.
4. Bu L, Liu Z, Zou J, Gao X, Bao Y, Qu S. Blocking central galanin receptors attenuates insulin sensitivity in myocytes of diabetic trained rats. J Neurosci Res 2013;91:971-7.
5. Desrois M, Sidell RJ, Gauguier D, Davey CL, Radda GK, Clarke K. Gender differences in hypertrophy, insulin resistance and ischemic injury in the aging type 2 diabetic rat heart. J Mol Cell Cardiol 2004;37:547-55.
6. Desrois M, Sidell RJ, Gauguier D, King LM, Radda GK, Clarke K. Initial steps of insulin signaling and glucose transport are defective in the type 2 diabetic rat heart. Cardiovasc Res 2004;61:288-96.
7. Fang P, Bo P, Shi M, Yu M, Zhang Z. Circulating galanin levels are increased in patients with gestational diabetes mellitus. Clin Biochem 2013;46:831-3.
8. Fang P, Shi M, Yu M, Guo L, Bo P, Zhang Z. Endogenous peptides as risk markers to assess the development of insulin resistance. Peptides 2014;51:9-14.
9. Fang P, Yu M, Shi MY, Zhang Z, Sui Y, Guo L, Bo P. Galanin peptide family as a modulating target for contribution to metabolic syndrome. Gen Comp Endocrinol 2012;179:115-20.
10. Fang P, Yu M, Guo L, Bo P, Zhang Z, Shi M. Galanin and its receptors: a novel strategy for appetite control and obesity therapy. Peptides 2012;36:331-9.
11. Gray S, Kim JK. New insights into insulin resistance in the diabetic heart. Trends Endocrinol Metab 2011;22:394-403.
12. Guo L, Shi M, Zhang L, Li G, Zhang L, Shao H, et al. Galanin antagonist increases insulin resistance by reducing glucose transporter 4 effect in adipocytes of rats. Gen Comp Endocrinol 2011;173:159-63.
13. Hafstad AD, Khalid AM, How OJ, Larsen TS, Aasum E. Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2007;292:E1288-94.
14. He B, Shi M, Zhang L, Li G, Zhang L, Shao H, et al. Beneficial effect of galanin on insulin sensitivity in muscle of type 2 diabetic rats. Physiol Behav 2011;103:284-9.
15. James DE, Brown R, Navarro J, Pilch PF. Insulin-regulatable tissues express a unique insulin-sensitive glucose transport protein. Nature 1988;333:183-5.
16. Jiang L, Shi M, Guo L, He B, Li G, Zhang L, et al. Effect of M35, a neuropeptide galanin antagonist on glucose uptake translated by glucose transporter 4 in trained rat skeletal muscle. Neurosci Lett 2009;467:178-81.
17. Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 2007;115:177-207.
18. Legakis IN. The role of galanin in metabolic disorders leading to type 2 diabetes mellitus. Drug News Perspect 2005;18:173-7.
19. Legakis I, Mantzouridis T, Mountokalakis T. Positive correlation of galanin with glucose in type 2 diabetes. Diabetes Care 2005;28:759-60.
20. Legalkis IN, Mantzouridis T, Mountokalakis T. Positive correlation of galanin with glucose in healthy volunteers during an oral glucose tolerance test. Horm Metab Res 2007;39:53-5.
21. Li SH, McNeill JH. In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats. Mol Cell Biochem 2001;17:121-9.
22. Lian Y, Sheng S, Fang P, Ma Y, Li J, Shi Q, et al. Exercise-induced galanin release facilitated GLUT4 translocation in adipocytes of type 2 diabetic rats. Pharmacol Biochem behav 2012;100:554-9.
23. Panagia M, Schneider JE, Brown B, Cole MA, Clarke K. Abnormal function and glucose metabolism in the type-2 diabetic db/db mouse heart. Can J Physiol Pharmacol 2007;85:289-94.
24. Paternostro G, Pagano D, Gnecchi-Ruscone T, Bonser RS, Camici PG. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res 1999;42:246-53.
25. Poritsanos NJ, Mizuno TM, Lautatzis ME, Vrontakis M. Chronic increase of circulating galanin levels induces obesity and marked alterations in lipid metabolism similar to metabolic syndrome. Int J Obes (Lond) 2009;33:1381-9.
26. Shah AM, Hung CL, Shin SH, Skali H, Verma A, Ghali JK, et al. Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. Am Heart J 2011;162:685-91.
27. Slot JW, Geuze HJ, Gigengack S, James DE, Lienhard GE. Translocation of the glucose transporter GLUT4 in cardiac myocytes of the rat. Proc Natl Acad Sci U S A 1991;88:7815-9.
28. Stanley WC, Hall JL, Hacker TA, Hernandez LA, Whitesell LF. Decreased myocardial glucose uptake during ischemia in diabetic swine. Metabolism 1997;46:168-72.
29. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997;30:527-32.
30. Tatemoto K, Rökaeus A, Jörnvall H, McDonald TJ, Mutt V. Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett 1983;164:124-8.
31. Tian R, Abel ED. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 2001;103:2961-6.
32. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.
33. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
34. Yun R, Dourmashkin JT, Hill J, Gayles EC, Fried SK, Leibowitz SF. PVN galanin increases fat storage and promotes obesity by causing muscle to utilize carbohydrate more than fat. Peptides 2005;26:2265-73.
35. Zhang Z, Sheng S, Guo L, Li G, Zhang L, Zhang L, et al. Intracerebroventricular administration of galanin antagonist sustains insulin resistance in adipocytes of type 2 diabetic trained rats. Mol Cell Endocrinol 2012;361:213-8.